|Company Name||Omeros Corporation|
On October 1, 2021, Omeros announced that the U.S. Food and Drug Administration (“FDA”) had identified deficiencies with the Company’s Biologics License Application for its drug candidate narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), which “preclude discussion of labeling and post-marketing requirements/commitments at this time.” Though the “FDA did not provide specific details of the deficiencies in its notification[,]” the Company stated that it “does not currently expect any resolution to occur by the October 17, 2021 target action date under the Prescription Drug User Fee Act (PDUFA).”
On this news, Omeros’s stock price fell $5.25 per share, or 38%, to close at $8.54 per share on October 1, 2021, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Omeros Corporation investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.